{"id":"W2160597466","doi":"10.1002/ana.23650","title":"Amyloid deposition, hypometabolism, and longitudinal cognitive decline","year":2012,"lang":"en","type":"article","venue":"Annals of Neurology","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":753,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute on Aging; Avid Radiopharmaceuticals; University of California, San Diego; National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes of Health Research; University of California, Los Angeles; National Institutes of Health; Servier; Elan; Astellas Pharma; Eisai; Genentech; University of Oxford; Northern California Institute for Research and Education; Pfizer; Biogen; BioClinica; Alzheimer's Association; Amorfix Life Sciences; Dana Foundation; Bayer HealthCare; Alzheimer's Disease Neuroimaging Initiative; Meso Scale Diagnostics; F. Hoffmann-La Roche; Medpace; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Amgen; Synarc; Foundation for the National Institutes of Health","keywords":"Cognitive decline; Neuroimaging; Positron emission tomography; Cognition; Internal medicine; Subclinical infection; Alzheimer's disease; Cog; Psychology; Medicine; Longitudinal study; Fluorodeoxyglucose; Dementia; Disease; Endocrinology; Pathology; Neuroscience","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}